HepTcell (FP-02.2) / Altimmune - LARVOL DELTA

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) (clinicaltrials.gov) - P2 | N=87 | Terminated | Sponsor: Altimmune, Inc. | Trial completion date: Sep 2024 ➔ Apr 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Oct 2023 ➔ Mar 2024; Did not meet endpoints

Trial completion date • Trial primary completion date • Trial termination • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update - "Altimmune, Inc...today announced financial results for the three months ended June 30, 2023, and provided a business update...Top-line data readout from 48-week MOMENTUM Phase 2 obesity trial expected in Q4 2023...Commenced enrollment in IMPACT Phase 2b NASH trial...Top-line results after 24 weeks of treatment are expected in the first quarter of 2025...Top-line data from Phase 2 clinical trial expected in Q1 2024...Cash, cash equivalents and short-term investments totaled $160.0 million as of June 30, 2023....Research and development expenses were $13.3 million for the three months ended June 30, 2023, compared to $16.0 million in the same period in 2022."

Commercial • P2 data • P2b data • Hepatitis B • Infectious Disease • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Altimmune, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2023 ➔ Sep 2024 | Trial primary completion date: Apr 2023 ➔ Oct 2023

Enrollment closed • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Altimmune, Inc. | Trial completion date: Feb 2023 ➔ Jul 2023 | Trial primary completion date: Mar 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update (GlobeNewswire) - "Altimmune, Inc...today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update....HepTcell: Enrollment ongoing for the Phase 2 clinical trial in chronic hepatitis B subjects, with study readout expected H1 2023...Readouts from this trial are expected to include virological markers of hepatitis B infection and functional cure."

Enrollment status • P2 data • Hepatitis B • Infectious Disease

ALTIMMUNE INC (ALT) Q2 2021 Earnings Call Transcript (The Motley Fool) - "Our other asset within the liver space is HepTcell and immunotherapeutic for chronic hepatitis B, that is in Phase 2 development...We have in HepTcell, one of the most clinically advanced immunotherapeutic candidates, and we are in the midst of executing on this international trial. We currently have sites in Canada, U.S., Germany and Spain to follow patients in a six-month dosing regimen. Considering the time to enroll HBV patients in this COVID environment and the duration of dosing, we expect to have data in the second half of next year."

P2 data • Hepatitis B • Infectious Disease

Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire) - "Research and development expenses were $11.9 million for the three months ended March 31, 2021, compared to $7.2 million in the prior period, representing an increase of $4.7 million....The HepTcell Phase 2 clinical efficacy trial data readout anticipated in 1H 2022..."

Commercial • P2 data • Hepatitis B • Infectious Disease

Altimmune to Present at Upcoming Scientific Conferences (GlobeNewswire) - "Altimmune, Inc...announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021...Altimmune will give an oral presentation at the Chronic Hepatitis B Drug Development Virtual Summit, taking place May 5-6, 2021, during which he will provide an overview of HepTcell™, a novel peptide-based immunotherapeutic being developed by Altimmune for the treatment of chronic hepatitis B (CHB)."

Clinical • Hepatitis B • Infectious Disease

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: Altimmune, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hepatitis B • Hepatology • Infectious Disease

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) (clinicaltrials.gov) - P2; N=80; Not yet recruiting; Sponsor: Altimmune, Inc.

Clinical • New P2 trial • Hepatitis B • Hepatology • Infectious Disease